Maple Syrup Urine Disease

Overview

Maple Syrup Urine Disease (MSUD) is a rare inherited disorder in which the body cannot properly break down the branched-chain amino acids leucine, isoleucine, and valine—protein building blocks found in food. Disease-causing variants in BCKDHA, BCKDHB, or DBT impair the branched-chain α-ketoacid dehydrogenase (BCKDH) enzyme complex, allowing leucine and related toxic metabolites to accumulate and damage the brain. Classic MSUD usually begins in the newborn period and, without rapid treatment, can cause poor feeding, lethargy, seizures, coma, and death; milder intermediate or intermittent forms can present later. GeneReviews: Maple Syrup Urine Disease

Newborn screening, specialized metabolic care, strict lifelong control of dietary branched-chain amino acids, medical formula, frequent blood monitoring, and emergency treatment during illness have greatly improved survival. In a 2024 German newborn-screening cohort, 97% of 33 individuals survived, although only 58% had cognitive function in the normal range, illustrating that early diagnosis improves outcomes but does not eliminate neurological risk. Treatment outcomes after newborn screening Liver transplantation can remove dietary restrictions and largely prevent metabolic crises, but it requires major surgery and lifelong immunosuppression and cannot reverse pre-existing cognitive or psychiatric effects. GeneReviews: Maple Syrup Urine Disease

Scope of Recent Research (2020–present)

MSUD cure research has become more active since 2020, led principally by gene-replacement studies using adeno-associated virus (AAV) vectors, messenger RNA (mRNA) packaged in lipid nanoparticles, and better natural-history datasets for future single-arm clinical trials. The central question is no longer whether partial restoration of BCKDH activity can improve disease—animal studies strongly suggest that it can—but how to safely provide durable correction in the liver, muscle, and especially brain early enough to prevent neurological injury. As of October 22, 2026, the leading curative candidates remain preclinical rather than proven in people. Trial-ready external controls for MSUD gene therapy

Major Breakthroughs and Emerging Therapies

AAV gene replacement has produced sustained rescue in several severe mouse models. In 2022, investigators used an AAV8 vector carrying human BCKDHA in newborn Bckdha-deficient mice; systemic treatment with a broadly active promoter enabled long-term survival, normal growth, and major correction of branched-chain amino acid and ketoacid abnormalities. Liver-only expression provided a smaller but durable benefit, supporting the idea that correction beyond the liver may be important. Neonatal AAV gene therapy for BCKDHA MSUD

A complementary strategy targets muscle as well as liver. A 2021 study in mice with DBT-related intermediate MSUD found that a muscle-tropic AAV9 vector with broad expression substantially improved survival, maintained near-normal blood branched-chain amino acid levels in higher-dose groups, and protected animals from a lethal high-protein dietary challenge. This approach reflects the major contribution of skeletal muscle to branched-chain amino-acid metabolism in humans. Muscle-directed AAV gene therapy in MSUD mice

Researchers have also expanded AAV gene replacement to the third principal MSUD gene. In a 2024 study, newborn mice lacking Bckdhb received AAV8 carrying human BCKDHB under a ubiquitous promoter; treatment achieved long-term rescue of a severe neonatal phenotype. Together with the earlier BCKDHA and DBT experiments, this establishes proof of principle for gene-specific replacement across the major genetic causes of MSUD. Neonatal AAV therapy for BCKDHB MSUD

The newest AAV work is focused on the brain. A 2026 mouse study used one AAV9 construct expressing both human BCKDHA and BCKDHB and reported survival to 140 days on unrestricted chow, restoration of several brain metabolites to the wild-type range, and normalization of brain 2-ketoisocaproate, a toxic leucine-derived ketoacid. Residual ketoacid elevations in blood showed that biochemical correction outside the brain was incomplete, but the findings strengthen the case that central nervous system delivery may be necessary for a truly disease-modifying treatment. Dual-gene AAV therapy restores brain metabolic balance in mice

A nonviral alternative is repeated mRNA replacement. In 2024, a collaboration involving the University of Pennsylvania and Moderna reported that lipid nanoparticles carrying mRNA for BCKDH components extended survival and lowered blood leucine in several MSUD mouse models, including models involving DBT, BCKDHA, and BCKDHB. Because mRNA does not permanently alter DNA and can be redosed, this platform could potentially address multiple genotypes, although it would likely require ongoing administration rather than a one-time cure. Lipid-nanoparticle mRNA therapy in MSUD mice

Clinical Trials and Experimental Approaches

No gene-replacement, gene-editing, or mRNA therapy for MSUD has yet reported human clinical efficacy results. Current translational work is preparing for the practical and regulatory challenge of testing a therapy in a very rare, life-threatening pediatric disease where randomized placebo-controlled trials may be infeasible. The 2026 MSUD Age-matched Standard Treatment Cohort (MATCH) followed 11 infants with classic MSUD from diagnosis to liver transplantation and defined trial-ready outcomes including crisis-management days, intact dietary protein tolerance, and blood alloisoleucine. The investigators’ simulations indicated that an appropriately designed single-arm gene-therapy study could use MATCH as an external comparator. MATCH external-control cohort

Recent registered human MSUD studies have primarily been observational or supportive-care research rather than curative intervention trials. For example, Children’s Hospital of Philadelphia completed an observational study of neurocognitive outcomes and quality of life in 44 adults with MSUD between 2021 and 2023, generating information that may help define meaningful long-term endpoints for future therapies. NCT04828863: Neurocognitive outcomes and quality of life in adults with MSUD

Methodologies and Scientific Approaches

MSUD researchers use genotype-specific mouse models lacking Bckdha, Bckdhb, or Dbt to test whether replacement of the missing BCKDH component rescues survival, growth, tolerance of dietary protein, and concentrations of leucine, alloisoleucine, and branched-chain ketoacids. AAV studies compare capsids, doses, routes of administration, and promoters that restrict gene expression to the liver or enable broader expression in liver, muscle, and other tissues. Neonatal AAV gene therapy for BCKDHA MSUD Muscle-directed AAV gene therapy in MSUD mice

The field is increasingly measuring disease in separate metabolic compartments rather than relying only on blood leucine. Recent work combines targeted metabolomics of blood and brain with neurotransmitter-related metabolites, magnetic resonance imaging and spectroscopy in large-animal models, and biomarkers such as alloisoleucine to assess both systemic and neurological correction. Dual-gene AAV therapy restores brain metabolic balance in mice MATCH external-control cohort

Leading Institutions and Funding

Major academic contributors include Institut Imagine, Inserm, AP-HP/Necker–Enfants Malades Hospital, and Université Paris Cité in France; the University of Pennsylvania Gene Therapy Program; Children’s Hospital of Philadelphia; the Clinic for Special Children; Mayo Clinic; and the University of Massachusetts Chan Medical School. University of Massachusetts Chan researchers Guangping Gao and Dan Wang partnered with ASC Therapeutics in 2021 to develop AAV-based MSUD gene therapy through preclinical development, manufacturing, regulatory preparation, and eventual investigational-new-drug submission. UMass Chan–ASC Therapeutics MSUD gene-therapy partnership

Public and philanthropic support is helping extend this work from mouse studies to brain-focused and large-animal studies. The U.S. National Institute of Neurological Disorders and Stroke awarded University of Massachusetts Medical School grant R01NS145295, with $613,528 in fiscal year 2025 and $652,662 in fiscal year 2026 reported through May 2026, to investigate in vivo gene transfer for MSUD neurological disease. NIH/NINDS award R01NS145295 The University of Pennsylvania’s Orphan Disease Center also supported a 2022–2023 project at Children’s Hospital of Philadelphia and Penn examining abnormal mTOR signaling—a pathway involved in cell growth and neurodevelopment—as a possible contributor to persistent neurological symptoms in MSUD. Orphan Disease Center mTOR project

Strengths, Limitations, and Challenges

The strongest evidence for a future cure is that multiple independent genetic strategies have rescued severe MSUD phenotypes in animals, and even partial BCKDH restoration can have large metabolic effects. Liver transplantation provides a clinical benchmark: restoring a fraction of normal whole-body BCKDH activity can remove dietary restrictions and protect against acute decompensation. GeneReviews: Maple Syrup Urine Disease The newer dual-gene study also suggests that restoring metabolism in the brain may correct toxic neurochemical changes more directly than strategies focused only on circulating leucine. Dual-gene AAV therapy restores brain metabolic balance in mice

Important barriers remain. AAV treatment may be limited by immune responses, dose-related toxicity, durability in a growing child, difficulty redosing after antibodies develop, and uncertainty over how much vector reaches the brain safely. mRNA-lipid nanoparticle therapy may avoid permanent gene delivery and permit repeat dosing, but its benefit will depend on reliable tissue targeting and frequent lifelong treatment. Animal rescue also does not establish that a treatment will prevent human cognitive, psychiatric, or developmental consequences, particularly when therapy begins after brain injury has already occurred. Lipid-nanoparticle mRNA therapy in MSUD mice NIH/NINDS award R01NS145295

Outlook and Future Directions

MSUD is scientifically closer to a potential genetic cure than it was in 2020, but it is not yet close to having a proven curative medicine for patients. The key milestones to watch are durable safety and efficacy in large-animal models, evidence that a vector can meaningfully correct both peripheral and brain metabolism, completion of manufacturing and toxicology studies, regulatory clearance for a first-in-human trial, and use of external-control frameworks such as MATCH to measure reductions in metabolic crises and improvements in protein tolerance and neurological outcomes. MATCH external-control cohort UMass Chan–ASC Therapeutics MSUD gene-therapy partnership

References

• GeneReviews: Maple Syrup Urine Disease — Strauss KA, Puffenberger EG, Carson VJ; University of Washington, updated 2024.
• Treatment outcomes after newborn screening — Kölker S et al.; Pediatrics, 2024.
• Neonatal AAV gene therapy for BCKDHA MSUD — Pontoizeau C et al.; Nature Communications, 2022.
• Muscle-directed AAV gene therapy in MSUD mice — Greig JA et al.; Molecular Genetics and Metabolism, 2021.
• Neonatal AAV therapy for BCKDHB MSUD — Pontoizeau C et al.; Journal of Inherited Metabolic Disease, 2024.
• Dual-gene AAV therapy restores brain metabolic balance in mice — Wang J et al.; Molecular Therapy, 2026.
• Lipid-nanoparticle mRNA therapy in MSUD mice — Greig JA et al.; Human Gene Therapy, 2024.
• MATCH external-control cohort — Brigatti KW et al.; Cell Reports Medicine, 2026.
• NCT04828863: Neurocognitive outcomes and quality of life in adults with MSUD — Children’s Hospital of Philadelphia, 2024.
• UMass Chan–ASC Therapeutics MSUD gene-therapy partnership — UMass Chan Medical School, 2021.
• NIH/NINDS award R01NS145295 — U.S. Department of Health and Human Services, 2026.
• Orphan Disease Center mTOR project — University of Pennsylvania Orphan Disease Center, 2022.